[Atherosclerosis and metabolic disease].
Cholesterol plays an important role in atherogenesis. Cholesterol-ester that has been carried by circulating low-density lipoprotein particles accumulates in the atherosclerotic plaque. Statins are considered the most potent and effective agents for reducing low-density lipoprotein cholesterol and the incidence of cardiovascular events. Total cholesterol and LDL cholesterol levels, however, are not always a useful marker for distinguishing patients with or without cardiovascular disease. Low levels of high-density lipoprotein cholesterol are the most predictive marker for cardiovascular disease. Low HDL cholesterol levels originate in some genetic and acquired diseases and conditions. Most cases of low HDL cholesterol associated with the development of atherosclerosis are of secondary origin, especially those associated with increasing triglyceride-rich lipoprotein. These conditions are present in insulin-resistant syndrome, namely metabolic syndrome. Type 2 diabetes mellitus and the closely related metabolic syndrome are associated with a significant risk for cardiovascular disease. Recent evidence suggests that both conditions are increasing in epidemic proportions. Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; and increased postprandial lipemia. All these lipoprotein disturbances accelerate atherosclerosis. It is likely that many patients will need lipid-modifying therapy to help prevent cardiovascular disease.
Tsuji
Masahiro
M
Institute of Medical Science, Health Sciences University of Hokkaido, Sapporo 002-8072.
Ishii
Jun
J
D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D001161:Arteriosclerosis / Q000209:etiology*; D002352:Carrier Proteins / Q000502:physiology; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL / Q000502:physiology; D008078:Cholesterol, LDL; D004777:Environment; D006023:Glycoproteins; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications*; D008019:Life Style; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D020125:Mutation, Missense; D019518:Postprandial Period; D012307:Risk Factors
D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006023:Glycoproteins